Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal

• Autor(a) principal: Borges, Vítor
• Data de Publicação: 2020
• Outros Autores: Isidro, Joana, Cortes-Martins, Helena, Duarte, Sílvia, Vieira, Luís, Leite, Ricardo, Gordo, Isabel, Caetano, Constantino P., Nunes, Baltazar, Sá, Regina, Oliveira, Ana, Guiomar, Raquel, Portuguese network for SARS-CoV-2 genomics (Consortium), Pinto, M. Alice, Rodrigues, Carina
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10198/27403
• topic: SARS-CoV-2; COVID-19; Genomic epidemiology; Mutation; Genetic variant; Spike; Fusion peptide; D839Y; Research Subject Categories::MEDICINE::Microbiology, immunology, infectious diseases

Genomic surveillance of SARS-CoV-2 was rapidly implemented in Portugal by the National Institute of Health in collaboration with a nationwide consortium of >50 hospitals/laboratories. Here, we track the geo-temporal spread of a SARS-CoV-2 variant with a mutation (D839Y) in a potential host-interacting region involving the Spike fusion peptide, which is a target motif of anti-viral drugs that plays a key role in SARS-CoV-2 infectivity. The Spike Y839 variant was most likely imported from Italy in mid-late February and massively disseminated in Portugal during the early epidemic, becoming prevalent in the Northern and Central regions of Portugal where it represented 22% and 59% of the sampled genomes, respectively, by 30 April. Based on our high sequencing sampling during the early epidemics [15.5% (1275/8251) and 6.0% (1500/24987) of all confirmed cases until the end of March and April, respectively], we estimate that between 14 March and 9 April (covering the epidemic exponential phase) the relative frequency of the Spike Y839 variant increased at a rate of 12.1% (6.1%–18.2%, CI 95%) every three days, being potentially associated with 24.8% (20.8–29.7%, CI 95%; 3177–4542 cases, CI 95%) of all COVID-19 cases in Portugal during this period. Our data support population/epidemiological (founder) effects contributing to the Y839 variant super spread. The potential existence of selective advantage is also discussed, although experimental validation is required. Despite huge differences in genome sampling worldwide, SARS-CoV-2 Spike D839Y has been detected in 13 countries in four continents, supporting the need for close surveillance and functional assays of Spike variants.